Resource table {#s0005}
==============

Name of stem cell lineKCL025InstitutionKing\'s College London, London UKDerivation teamNeli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma StephensonContact person and emailDusko Ilic, email: <dusko.ilic@kcl.ac.uk>Date archived/stock dateMar 31, 2011Type of resourceBiological reagent: cell lineSub-typeHuman pluripotent stem cell lineOriginHuman embryoKey marker expressionPluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activityAuthenticationIdentity and purity of line confirmedLink to related literature\
(direct URL links and full references)1)Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122--128.doi: 10.3109/14653249.2011.623692\
<http://www.ncbi.nlm.nih.gov/pubmed/22029654>\
2)Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366--1381.doi: 10.1038/nprot.2012.080\
<http://www.ncbi.nlm.nih.gov/pubmed/22722371>Information in public databasesKCL025 is a National Institutes of Health (NIH) registered hESC line\
NIH Registration Number: 0221\
NIH Approval Number: NIHhESC-13-0221\
<http://grants.nih.gov/stem_cells/registry/current.htm?id=661>EthicsThe hESC line KCL025 is derived under license from the UK Human Fertilisation and Embryology Authority (research license numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90).\
Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.

Resource details {#s0010}
================

Consent signedOct 28, 2010Embryo usedMar 03, 2011UK Stem Cell Bank Deposit ApprovalDec 01, 2011\
Reference: SCSC11-48SexMale 46, XYGradeResearchDisease status\
([Fig 1](#f0005){ref-type="fig"})Autosomal dominant mutation in the *NF1* gene encoding neurofibromin (c.3739--3742 ΔTTTG)Karyotype (aCGH)NDDNA fingerprintNDHLA typingHLA-A: 11,26; -B: 55,57; -C 03,06; DRB1: 04,07Viability testingPassPluripotent markers\
(immunostaining)\
([Fig 2](#f0010){ref-type="fig"})NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityThree germ layers differentiation in vitro\
(immunostaining)\
([Fig 3](#f0015){ref-type="fig"})Endoderm: AFP (α-fetoprotein)\
Ectoderm: TUBB3 (tubulin, β3 class III)\
Mesoderm: ACTA2 (actin, α2, smooth muscle)Sibling lines availableKCL024[^1]

We generated KCL025 clinical grade hESC line following protocols, established previously ([@bb0015], [@bb0030]). The expression of the pluripotency markers was tested after freeze/thaw cycle. Differentiation potential into three germ layers was verified in vitro.

Materials and methods {#s0015}
=====================

Consenting process {#s0020}
------------------

We distribute Patient Information Sheet (PIS) and consent form to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent were mailed to them. If in the meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (PGD-V.8) were created on Jul. 01, 2010. HFEA Code of Practice that was in effect at the time of document creation: Edition 8--R.2 (<http://www.hfea.gov.uk/2999.html>). The donor couple signed the consent on Oct. 28, 2010. HFEA Code of Practice that was in effect at the time of donor signature: Edition 8--R.2. HFEA Code of Practice Edition 8--R.2 was in effect 07 Apr. 2010--Apr. 06, 2011.

Embryo culture and micromanipulation {#s0025}
------------------------------------

Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details ([@bb0015], [@bb0030]). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFFs).

Cell culture {#s0030}
------------

ICM plated on mitotically inactivated HFF was cultured as described ([@bb0015], [@bb0030]). TE cells were removed mechanically from outgrowth ([@bb0005], [@bb0010]). hESC colonies were expanded and cryopreserved at the third passage.

Viability test {#s0035}
--------------

Straws with the earliest frozen passage (p.2--3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were part frozen and part subjected to standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, mycoplasma).

Pluripotency markers {#s0040}
--------------------

Pluripotency was assessed using two different techniques: enzymatic activity assay \[alkaline phosphatase (AP) assay\] and immunostaining as described ([@bb0015], [@bb0030]; [@bb0025]).

Differentiation {#s0045}
---------------

Spontaneous differentiation into three germ layers was assessed in vitro as described ([@bb0015], [@bb0030], [@bb0025]).

HLA typing {#s0050}
----------

HLA-A, -B and -DRB1 typing was performed with a PCR sequence-specific oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybridization protocol at the certified Clinical Transplantation Laboratory, Guy\'s and St Thomas\' NHS Foundation Trust and Serco Plc. (GSTS) Pathology (Guy\'s Hospital, London, UK) as described ([@bb0020]).
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===========================
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![Genetic pedigree tree. Male donor was carrying an autosomal dominant mutation c.3739--3742 ΔTTTG in the *NF1* gene. The couple undergoing IVF and prenatal genetic diagnosis had 6 embryos in this particular cycle. Embryos carrying the mutation in the *NF1* gene were donated for research. We derived two hESC lines: KCL024 and KCL025.](gr1){#f0005}

![Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress fibers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.](gr2){#f0010}

![Differentiation of three germ layers in vitro is confirmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm and α-fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 100 μm.](gr3){#f0015}

[^1]: ND, not determined.
